Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Scuoppo C, Wang J, Persaud M, Mittan SK, Basso K, Pasqualucci L, et al. Repurposing dasatinib for diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2019;116(34):16981-16986.

Baum JE, Soong L, Scognamiglio T, Margolskee EM, Hoda RS, Rao R. Cytological diagnosis of papillary thyroid carcinoma with tall cells on ThinPrep liquid-based cytology. Diagn Cytopathol. 2019;47(6):541-546.

Nissim S, Leshchiner I, Mancias JD, Greenblatt MB, Maertens O, Cassa CA, et al. Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer. Nat Genet. 2019;51(9):1308-1314.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, et al. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clin Cancer Res. 2019;25(1):43-51.

Sun L, Thorson T, Zhu R, Huo J, Tong J, Rodgers WH, et al. A case report of parotid mammary analogue secretory carcinoma and reviews. Int J Surg Case Rep. 2019;55:88-91.

Canver MC, Satlin MJ, Westblade LF, Kreiswirth BN, Chen L, Robertson A, et al. Activity of Imipenem-Relebactam and Comparator Agents against Genetically Characterized Isolates of Carbapenem-Resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2019;63(9).

Cross T, Ransegnola B, Shin J-, Weaver A, Fauntleroy K, VanNieuwenhze MS, et al. Spheroplast-Mediated Carbapenem Tolerance in Gram-Negative Pathogens. Antimicrob Agents Chemother. 2019;63(9).

Cohn CS, Allen ES, Cushing MM, Dunbar NM, Friedman DF, Goel R, et al. Critical developments of 2018: A review of the literature from selected topics in transfusion. A committee report from the AABB's Clinical Transfusion Medicine Committee. Transfusion. 2019;59(8):2733-2748.

Melis M, Tang X-, Trasino SE, Patel VM, Stummer DJ, Jessurun J, et al. Effects of AM80 compared to AC261066 in a high fat diet mouse model of liver disease. PLoS One. 2019;14(1):e0211071.

Marzio A, Puccini J, Kwon Y, Maverakis NK, Arbini A, Sung P, et al. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers. Mol Cell. 2019;73(2):224-237.e6.